Ashiya, Japan

Itaru Mita

This inventor holds 2 USPTO granted patents. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 1976-1985.


% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • Ashiya, JA (1976)
  • Ashiya, JP (1985)

Company Filing History:


Years Active: 1976-1985

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Itaru Mita

Introduction

Itaru Mita is a notable inventor based in Ashiya, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various health issues. With a total of 2 patents, Mita's work is recognized for its potential impact on medical treatments.

Latest Patents

Mita's latest patents include innovative compounds that are useful in treating liver damage and metabolic disorders. One of his patents focuses on Aletheine derivatives, which are beneficial for the treatment of liver damage. Another patent involves N-(mercaptoacyl)amino acids, which are compounds useful for prophylaxis and therapy in treating metabolic disorders such as nosotoxicosis due to heavy metal radiation, diabetes, or hepatitis.

Career Highlights

Itaru Mita is associated with Santen Pharmaceutical Co., Ltd., where he continues to contribute to pharmaceutical research and development. His work is characterized by a commitment to improving health outcomes through innovative solutions.

Collaborations

Mita has collaborated with esteemed colleagues such as Shigeo Okumura and Shigeru Yamabe. These collaborations have further enhanced the scope and impact of his research.

Conclusion

Itaru Mita's contributions to the field of pharmaceuticals through his patents and collaborations highlight his dedication to innovation in medical treatments. His work continues to pave the way for advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…